NCT05997212 Effect of Repetitive TMS on Executive Function in Alcohol Use Disorder
| NCT ID | NCT05997212 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Universidad Nacional Autonoma de Mexico |
| Condition | Alcohol Use Disorder |
| Study Type | INTERVENTIONAL |
| Enrollment | 44 participants |
| Start Date | 2024-03-16 |
| Primary Completion | 2025-07-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 44 participants in total. It began in 2024-03-16 with a primary completion date of 2025-07-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Alcohol Use Disorder (AUD) is a major public health problem that affects the physical, social, family, and mental integrity of the sufferer. Behavioral self-regulation is compromised in AUD, and a benefit has been reported with the application of repetitive transcranial magnetic stimulation and emotional self-regulation. The aim of this study is to investigate the efficacy of high-frequency rTMS to improve executive functions in patients in abstinence from AUD.
Eligibility Criteria
Inclusion Criteria: * Men and women of 25 to 59 years old * The reading level of at least 6th grade of primary (equivalent to fifth grade of elementary school). * Alcohol users with and AUDIT ≥ 20 puntos * Abstinence from alcohol consumption from 8 weeks to 5 years, with CIWA-Ar scale scores ≤ 9 points. * No disabling neuropsychiatric conditions (i.e. Schizophrenia) * No substance use disorders except alcohol and nicotine. * BrAC (Breath Alcohol) = 0.00 mg/dl in each of the assessments. * No traces of alcohol consumption using urine test strips. * No contraindications for TMS therapy. Exclusion Criteria: * Individuals with symptoms of severe agitation or who are unable to cooperate in the study * History of epilepsy * Sudden onset of stroke, focal neurological findings such as hemiparesis, sensory loss, visual field deficits and lack of coordination. * Seizures or gait disturbances * History of severe psychiatric disorders. * Alterations in a conventional electroencephalogram. * Pacemakers or intracranial metallic objects. Elimination criteria * At the subject's request * The presence of adverse incidents that deteriorate the subject's health and would limit continuation of rTMS treatment. * Exacerbation of cognitive or behavioral symptoms during treatment.
Contact & Investigator
Eduardo A Garza-Villarreal, MD, PhD
PRINCIPAL INVESTIGATOR
Universidad Nacional Autonoma de Mexico
Frequently Asked Questions
Who can join the NCT05997212 clinical trial?
This trial is open to participants of all sexes, aged 25 Years or older, up to 59 Years, studying Alcohol Use Disorder. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05997212 currently recruiting?
Yes, NCT05997212 is actively recruiting participants. Contact the research team at alejandraloc@comunidad.unam.mx for enrollment information.
Where is the NCT05997212 trial being conducted?
This trial is being conducted at Querétaro City, Mexico.
Who is sponsoring the NCT05997212 clinical trial?
NCT05997212 is sponsored by Universidad Nacional Autonoma de Mexico. The principal investigator is Eduardo A Garza-Villarreal, MD, PhD at Universidad Nacional Autonoma de Mexico. The trial plans to enroll 44 participants.